Atrovent

Atrovent is an inhaler containing ipratropium bromide, a short-acting muscarinic antagonist (SAMA) bronchodilator. It opens up the airways but works through a different mechanism from Ventolin. In the UK it's used most often in chronic obstructive pulmonary disease (COPD) and in some specific asthma situations — for example as an add-on during severe attacks, or in patients who can't tolerate salbutamol because of side effects like tremor or palpitations.

Both Ventolin and Atrovent open up the airways, but they push different buttons to get there. Ventolin tells the airway muscles to relax by stimulating beta-2 receptors. Atrovent works by blocking a different receptor — the muscarinic receptor — which the body uses to keep the airways slightly tightened in the background. By blocking that signal, Atrovent allows the airways to ease open. A useful way of thinking about it is that Ventolin actively pushes the muscle to relax, while Atrovent removes a constant pull that's keeping the muscle tight.

Atrovent is slower off the mark than Ventolin, taking around 15 minutes to start having a meaningful effect, with peak effect around an hour or two later and a duration of roughly four to six hours. This slower onset is one of the reasons it isn't used as a first-line rescue inhaler in asthma — Ventolin is faster when you need quick relief.

Common reasons include COPD (where SAMAs and their longer-acting cousins are particularly useful), people who experience strong tremor or palpitations on salbutamol, and as an add-on alongside Ventolin in moderate to severe asthma flares — the two work via different routes, so combining them can give a bigger effect than either alone.

The standard adult dose from a metered-dose inhaler is one or two puffs (each 20 micrograms) up to four times a day. Because it's slower-acting, it's not ideal for use in the moment of a sudden symptom — it's more often used regularly or as part of a wider plan agreed with your clinician.

The most commonly reported are dry mouth, an unusual or bitter taste, headache, and occasional cough or throat irritation. A particular thing to watch for is accidental contact with the eyes — Atrovent spray getting into the eye can cause blurred vision, eye pain, or in people prone to it, a flare of acute angle-closure glaucoma. Using a spacer with a mouthpiece, or being careful with technique, almost eliminates this risk.

Yes. Atrovent should be used carefully in people with narrow-angle glaucoma, prostate enlargement, or bladder outflow problems, because anticholinergic medicines can worsen all three. None of these are absolute reasons not to use it — they just mean a clinician should weigh the decision and advise on technique to minimise systemic absorption.

Atrovent has been used in children and during pregnancy where benefits clearly outweigh risks, particularly in acute severe attacks. As with most asthma medicines in pregnancy, the underlying message is the same: poorly controlled disease is more harmful than the medicines used to treat it. Any decision should be guided by a clinician.

Yes — and combining them is used to treat severe asthma flares and in COPD. Because the two work through different mechanisms, the airway opens up via two routes rather than one. In day-to-day life, you'd usually only do this on the explicit advice of a prescriber, or as part of a written asthma action plan.